Abstracts Archive - Page 787 of 2425 - ACR Meeting Abstracts

Abstract Number: 1985 • ACR Convergence 2020
Validity and Reliability of Four Parent/Patient Reported Outcome Measures for Juvenile Idiopathic Arthritis
Chiara Trincianti¹, E. H. Pieter Van Dijkhuizen², Serena Calandra³, Helga Sanner⁴, Tamas Constantin⁵, Troels Herlin⁶, Marco Cattalini⁷, Flavio Sztajnbok⁸, Despoina Maritsi⁹, Nicolino Ruperto¹⁰, Angelo Ravelli¹¹ and Alessandro Consolaro¹¹, ¹Istituto Giannina Gaslini, Genova, Liguria, Italy, ²Wilhelmina Children’s Hospital, Utrecht, Netherlands, ³IRCCS Istituto Giannina Gaslini, Genoa, Liguria, Italy, ⁴Oslo University Hospital, Oslo, Norway, ⁵Semmelweis University, Budapest, Hungary, ⁶Aarhus University Hospital, Aarhus, Denmark, ⁷Università di Brescia, Brescia, Italy, ⁸Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁹National and Kapodistrian University of Athens, Athens, Greece, ¹⁰Istituto Giannina Gaslini, Genova, Italy, ¹¹Università degli Studi di Genova, Genoa, Italy
Background/Purpose: In the last years, the interest in the assessment of parent- and child-reported outcomes (PCROs) in paediatric rheumatic diseases is gaining increasing importance. These…
Abstract Number: 1986 • ACR Convergence 2020
Determinants of Variation in Pediatric Systemic Lupus Erythematosus Care Delivery
Jon Burnham¹, Rosemary Peterson¹, Joy Ukaigwe¹, Lynsey Cecere¹, Andrea Knight² and Joyce Chang¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Division of Rheumatology, The Hospital for Sick Children and Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with pediatric systemic lupus erythematosus (pSLE) receive only a fraction of recommended care. Moreover, variation in care delivery likely contributes to pervasive racial…
Abstract Number: 1987 • ACR Convergence 2020
Predictors of Adverse Outcomes in Patients with Childhood-Onset Systemic Lupus Erythematosus Transitioning to Adult Care
Nicole Bitencourt¹, Una Makris¹, Elizabeth Solow¹, Tracey Wright² and Bonnie Bermas³, ¹UT Southwestern Medical Center, Dallas, TX, ²UT Southwestern, Plano, TX, ³UTSouthwestern.edu, Dallas, TX
Background/Purpose: The transition from pediatric to adult care is a vulnerable period and is linked to increased healthcare utilization and poor outcomes. We sought to…
Abstract Number: 1988 • ACR Convergence 2020
Skin Disease More Recalcitrant to Intervention Than Muscle Disease: A Long-Term Prospective Study of 184 Children with Juvenile Dermatomyositis
Andi Wang¹, Gabrielle Morgan², Chiang-Ching Huang³, Amy Paller⁴ and Lauren Pachman⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ³Joseph J. Zilber School of Public Health, Milwaukee, ⁴Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, ⁵Department of Pediatrics, Northwestern University Feinberg School of Medicine; The Ann and Robert H. Lurie Children's Hospital of Chicago, Division of Pediatric Rheumatology; The CureJM Center of Excellence in Juvenile Myositis Research and Care, The Stanley Manne Children's Research Center of Chicago, Lake Forest, IL
Background/Purpose: Persistent skin manifestations, in particular calcinosis, contribute to significant morbidity in patients with JDM. The goal of this study was to compare the course…
Abstract Number: 1989 • ACR Convergence 2020
NXP2 Autoantibodies Link to Interferon Signature in Juvenile Myositis Lesional Skin
Jessica Turnier¹, Lauren Pachman², Lori Lowe³, Alex Tsoi³, Sultan Elhaj¹, Rajasree Menon¹, Maria Amoruso², Gabrielle Morgan⁴, Johann Gudjonsson⁵, Celine Berthier³ and J Michelle Kahlenberg¹, ¹University of Michigan, Ann Arbor, MI, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³University of Michigan, Ann Arbor, ⁴Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵University of Michigan, Ann ArborUniversity of Michigan
Background/Purpose: Skin inflammation can herald systemic disease in juvenile myositis (JM), yet we lack an understanding of pathogenic mechanisms driving skin inflammation in JM. The…
Abstract Number: 1990 • ACR Convergence 2020
Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis
Hanna Kim¹, Lylan Bergeron², Samantha Dill², Michelle O'Brien², Laura Vian³, Minal Jain⁴, Manuk Manukyan², Xiaobai Li⁵, Shajia Lu³, Wanxia L. Tsai³, Kalyani Mishra Thakur⁶, Yinghui Shi⁶, Massimo Gadina⁷, April Brundidge², Michelle Millwood², Lisa G. Rider⁸ and Robert Colbert², ¹Juvenile Myositis Pathogenesis and Therapeutics Unit / NIAMS / National Institutes of Health, Bethesda, MD, ²Pediatric Clinical Trials Unit and Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ³Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ⁴Rehabilitation Medicine Department, Physical Therapy Section, Clinical Research Center, NIH, Bethesda, MD, ⁵Biostatistics and Clinical Epidemiology Service, Clinical Center, NIH, Bethesda, MD, ⁶Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, ⁸Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Garrett Park, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications.…
Abstract Number: 1991 • ACR Convergence 2020
Abatacept Treatment Reduces Cutaneous and Joint Activity in Juvenile Localized Scleroderma
Suzanne Li¹, Sarah Ishaq², Mary Buckley³, Kathryn Torok⁴, Barbara Edelheit⁵, Kaleo Ede⁶, Christopher Liu⁷ and C. Egla Rabinovich⁸, ¹Hackensack University Medical Center, Hackensack, ²Montclair State University, Montclair, ³Duke University, Durham, NC, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Conneticut Children's Medical Center, Hartford, ⁶Phoenix Children's Hospital, Phoenix, AZ, ⁷U Pittsburgh, Pittsburgh, ⁸Duke University Hospital, Durham, NC
Background/Purpose: Juvenile localized scleroderma (jLS) is an autoimmune disease commonly associated with damage. Damage includes dyspigmentation, tissue atrophy, arthropathy, hemiatrophy, vision loss, and seizures. To…
Abstract Number: 1992 • ACR Convergence 2020
Longitudinal Evaluation of Axonal Dysfunction, Neuronal Markers and Serum Cytokines in Childhood-onset Systemic Lupus Erythematosus
Renan Frittoli¹, Danilo Rodrigues¹, Aline Lapa¹, Mariana Postal¹, Roberto Marini¹, Gabriela Castellano¹, Fernando Cendes¹, Leticia Rittner¹ and Simone Appenzeller¹, ¹UNICAMP, Campinas, Brazil
Background/Purpose: To analyze 1H-MRS brain metabolites in a longitudinal study and to determine clinical, laboratory and treatment features associated with its occurrence. To determine, additionally…
Abstract Number: 1993 • ACR Convergence 2020
Cardiovascular Risk in Rheumatoid Arthritis Patients Treated with Methotrexate versus Hydroxychloroquine
Mengdong He¹, Ajinkya Pawar¹, Rishi Desai¹, Robert Glynn¹, Hemin Lee¹, Michael Weinblatt¹, Daniel H Solomon¹ and Seoyoung Kim¹, ¹Brigham and Women's Hospital, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a known risk factor for cardiovascular (CV) events. While most RA patients use conventional disease-modifying antirheumatic drugs (DMARDs) such as…
Abstract Number: 1994 • ACR Convergence 2020
Rheumatoid Arthritis Improvement After Exposure to an Anti-Inflammatory “ITIS” Diet Is Associated with Changes of Gut Microbiome and Systemic Metabolome
Roxana Coras¹, Cameron Martino², Julia Gauglitz³, Anupriya Tripathi³, Alan Jarmusch⁴, Francesca Cedola⁵, Marta Fernandez Bustamante⁶, Meritxall Agustín-Perez⁷, Maram Alharthi⁸, Susan Lee⁸, Abha Singh⁸, Soo In Choi⁸, Tania Rivera⁸, Katherine Nguyen⁸, Tatyana Shekhtman⁹, Tiffany Holt¹⁰, Shahrokh Golshan¹¹, Rob Knight³, Pieter Dorrestein¹² and Monica Guma¹³, ¹University of California San Diego, La Jolla, CA, ²Bioinformatics and Systems Biology, University of California San Diego, San Diego, ³University of California San Diego, San Diego, ⁴Univesity of California San Diego, San Diego, ⁵Hospital Policlinico Tor Vergata, Rome, Italy, ⁶Departement of Medicine, Division of Rheumatology, University of California San Diego, San Diego, ⁷Department of Medicine, University of California San Diego, San Diego, San Diego, ⁸Department of Medicine, Division of Rheumatology, University of California San Diego, San Diego, ⁹Department of Psychiatry, University of California, San Diego, San Diego, ¹⁰Center for Integrative Nutrition, University of California San Diego, San Diego, ¹¹Department of Psychiatry, University of California San Diego, San Diego, CA, USA, San Diego, ¹²Department of Pharmacology and Pediatrics, University of California San Deigo, San Diego, ¹³Division of Rheumatology, University of California San Diego, Department of Medicine, Autonomous University of Barcelona, La Jolla, CA
Background/Purpose: A new dimension has been added to the link between diet and health, the gut microbiome. Of particular interest is the influence of diet…
Abstract Number: 1995 • ACR Convergence 2020
Non-invasive Vagus Nerve Stimulation Improves Signs and Symptoms of Rheumatoid Arthritis: Results of a Pilot Study
Sara Marsal¹, Hector Corominas², Juan Jose De Agustin De Oro³, Carolina Perez Garcia⁴, Maria Lopez Lasanta³, Helena Borrell³, Delia Reina⁵, Raimon Sanmartí⁶, Francisco Javier Narváez⁷, Clara Franco-Jarava⁸, Charles Peterfy⁹, Jose Antonio Narvaez¹⁰, Vivek Sharma¹¹, Konstantinos Alataris¹¹, Mark Genovese¹² and Matthew Baker¹³, ¹Hospital Universitari Vall d'Hebron, Barcelona, Spain, ²Institut Rec. Hospital de la Santa Creu I Sant Pau., Barcelona, Spain, ³Hospital Universitari Vall d’Hebron, Barcelona, Spain, ⁴Hospital Universitari Parc Salut Mar, Barcelona, Spain, ⁵Hospital Moises Broggi, Barcelona, Spain, ⁶Hospital Universitari Clínic de Barcelona, Barcelona, Catalonia, Spain, ⁷Hospital Bellvitge, BARCELONA, Spain, ⁸1Hospital Universitari Vall d’Hebron, Barcelona, Spain, ⁹Spire Sciences, Inc., Boca Raton, FL, ¹⁰Clinica Diagonal, Barcelona, Spain, ¹¹Vorso Corp, Redwood CIty, CA, ¹²Stanford University Medical Center, Palo Alto, CA, ¹³Stanford University, Menlo Park, CA
Background/Purpose: Vagus nerve stimulation (VNS) has been shown to improve rheumatoid arthritis (RA) disease severity in patients with refractory disease (1,2). A multi-center pilot study…
Abstract Number: 1996 • ACR Convergence 2020
Evaluation of Response to Pneumococcal Vaccination in Patients with Rheumatoid Arthritis Receiving Upadacitinib: Results from a Phase 2 Open-Label Extension Study
Kevin Winthrop¹, Juan Vargas², Edit Drescher³, Conrado Garcia⁴, Alan Friedman⁵, Jeffrey Enejosa⁵, Nasser Khan⁵, Yihan Li⁵, Justin Klaff⁵ and Alan Kivitz⁶, ¹Oregon Health & Science University, Portland, OR, ²Quantum Research, Puerto Varas, Chile, ³Veszprém Csolnoky Ferenc County Hospital, Veszprém, Hungary, ⁴Hospital General de México "Dr. Eduardo Liceaga", Mexico, Mexico, ⁵AbbVie Inc., North Chicago, IL, ⁶Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA
Background/Purpose: Pneumococcal vaccination is recommended in patients with RA who are receiving conventional synthetic/biologic DMARDs.1 Upadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor engineered to…
Abstract Number: 1997 • ACR Convergence 2020
Immunogenicity of Adjuvanted Herpes Zoster Subunit Vaccine in Rheumatoid Arthritis Patients Treated with Janus Kinase Inhibitors and Controls: Preliminary Results
Hanna Källmark¹, Birgitta Gullstrand², Johanna Nagel³, Jon Einarsson¹, Göran Jönsson⁴, Fredrik Kahn⁵, Robin Kahn⁶, Anders Bangtsson², Tomas Bergström⁷ and Meliha Kapetanovic¹, ¹Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden and Skåne University Hospital Sweden., Lund, Sweden, ²Department of Rheumatology, Clinical Sciences, Lund University Sweden, Lund, Sweden, ³Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, Lund, Sweden, ⁴Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Infection Medicine, Lund, Sweden, Lund, Sweden, ⁵Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden, Lund, Sweden, ⁶Department of Clinical Sciences Lund, Section of Pediatrics, Lund University, Lund, Sweden; Wallenberg Centre of Molecular Medicine, Lund University, Lund, Sweden, ⁷Department of Infectious Diseases, Section for Clinical Virology, Institute of Biomedicine, University of Gothenburg, Sweden, Gothenburg, Sweden
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of contracting herpes zoster (HZ) and treatment with JAnus Kinase inhibitors (JAKi) further adds on…
Abstract Number: 1998 • ACR Convergence 2020
Ten-year Analysis of the Risk of Severe Outcomes Related to Very Low-dose Glucocorticoids in Early Rheumatoid Arthritis
Camille Roubille¹, Amandine Coffy², Nathalie Rincheval², Jean Pierre Daures², René-Marc Flipo³, Maxime Dougados⁴ and Bernard Combe⁵, ¹CHU LAPEYRONIE, Montpellier, France, ²INSERM, Montpellier, France, ³Univ-Lille, CHU Lille, department of rheumatology, Lille, France, ⁴Department of Rheumatology, Hopital Cochin, Université de Paris, Paris, France, ⁵University of Montpellier, Montpellier, France
Background/Purpose: Although glucocorticoids (GC) remain an essential part of the therapeutic strategy in Rheumatoid Arthritis (RA), the long-term risk of adverse events of low-dose GC…
Abstract Number: 1999 • ACR Convergence 2020
Hydroxychloroquine Is Not Cardiotoxic in Patients with Rheumatoid Arthritis
Jose Felix Restrepo¹, Agustin Escalante¹, Daniel Battafarano², Carlos Lorenzo³ and Inmaculada Del Rincon¹, ¹University of Texas Health Science Center at San Antonio/ Department of Medicine/ Rheumatology, San Antonio, TX, ²San Antonio Military Medical Center, San Antonio, TX, ³University of Texas Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: Hydroxychloroquine (HCQ) has been proposed as a potential treatment for COVID-19, but early reports suggested that it could have cardiotoxic effects. Despite widespread and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.